The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Does Riluzole reduce the incidence of chemotherapy-induced nerve injury in patients with colorectal cancer?
Scientific title
NEU-HORIZONS: The neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin neurotoxicity in patients with colorectal cancer
Secondary ID [1] 262128 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Oxaliplatin-induced neurotoxicity 265801 0
Colorectal cancer 265875 0
Condition category
Condition code
Neurological 265957 265957 0 0
Other neurological disorders
Cancer 266006 266006 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Study type
Description of intervention(s) / exposure
Patients receiving oxaliplatin chemotherapy for colorectal cancer will be randomised into either the study drug arm or placebo control arm. Participants will be started on either riluzole 50 mg oral tablet twice daily or the twice daily lactose placebo tablet. Following randomisation, therapy will be continued for the duration of oxaliplatin treatment (4-6 months) and for 2 weeks following treatment cessation.
Intervention code [1] 264544 0
Comparator / control treatment
Routine clinical care involving standard review by oncology physician and placebo lactose tablet. Symptomatic relief of neuropathic symptoms as required.
Control group

Primary outcome [1] 266708 0
To assess whether treatment with riluzole results in a reduction in the development of chronic neuropathy and neuropathic symptoms

The severity of neuropathy will be assessed using the Total Neuropathy Score (TNS). This will be used to evaluate neuropathy in a number of different categories; sensory neuropathic symptoms, examination findings and nerve conduction results.
Timepoint [1]